Floatz logo

Eloxatin

Central Nervous System Lymphoma

The Lymphoma Academic Research OrganisationPhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the Central Nervous System Lymphoma cohort.

Asset / SponsorPhaseRating
Busulphan
Sichuan University
Phase 2/3BB
CARMUSTINE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BB
Thiotepa
Zhejiang Cancer Hospital
Phase 2B
Acalabrutinib
Jonsson Comprehensive Cancer Center
Phase 2B
Pomalidomide
Beijing Tongren Hospital
Phase 2B

View all 36 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →